Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 2, 2016, Pages 122-132

  Younossi, Zobair M ^a,g   Stepanova, Maria ^b   Charlton, Michael ^c   Curry, Michael P ^d   O'Leary, Jacqueline G ^e   Brown, Robert S ^f   Hunt, Sharon ^g  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RIBAVIRIN; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; SOFOSBUVIR; VELPATASVIR;

ABSENTEEISM; ACUTE BRAIN DISEASE; ACUTE ON CHRONIC LIVER FAILURE; ADULT; ANEMIA; ARTICLE; ASSESSMENT OF HUMANS; ASTHENIA; BODY MASS; CHRONIC LIVER DISEASE QUESTIONNAIRE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MILD HEPATIC IMPAIRMENT; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL WELL-BEING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; SKIN DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WORK PRODUCTIVITY ACTIVITY INDEX; ADOLESCENT; AGED; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; FOLLOW UP; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84996600359     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30009-7     Document Type: Article

References (36)

1. 1 Klenerman, P, Fitzmaurice, K, An update on hepatitis C virus. Clin Med 15:suppl 6 (2015), 33–36.
2. 2 Vera-Llonch, M, Martin, M, Aggarwal, J, et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 38 (2013), 124–133.
3. 3 Aggarwal, J, Vera-Llonch, M, Donepudi, M, Suthoff, E, Younossi, Z, Goss, TF, Work productivity among treatment-naive patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. J Viral Hepat 22 (2015), 8–17.
4. 4 Banerjee, D, Reddy, KR, Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 43 (2016), 674–696.
5. 5 Asselah, T, Boyer, N, Saadoun, D, Martinot-Peignoux, M, Marcellin, P, Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36:suppl 1 (2016), 47–57.
6. 6 Lam, BP, Jeffers, T, Younoszai, Z, Fazel, Y, Younossi, ZM, The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 8 (2015), 298–312.
7. 7 Younossi, Z, Henry, L, Systematic review: patient-reported outcomes in chronic hepatitis C—the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 41 (2015), 497–520.
8. 8 Younossi, Z, Henry, L, The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 46:suppl 5 (2014), S186–S196.
9. 9 Younossi, ZM, Stepanova, M, Henry, L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 60 (2014), 741–747.
10. 10 Younossi, ZM, Stepanova, M, Henry, L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 12 (2014), 1349–1359.
11. 11 Younossi, ZM, Stepanova, M, Zeuzem, S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 61 (2014), 228–234.
12. 12 Younossi, ZM, Stepanova, M, Pol, S, Bronowicki, JP, Carrieri, MP, Bourlière, M, The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int 36 (2016), 42–48.
13. 13 Younossi, ZM, Stepanova, M, Afdhal, N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 63 (2015), 337–345.
14. 14 Younossi, ZM, Stepanova, M, Nader, F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 59 (2014), 2161–2169.
15. 15 Younossi, ZM, Stepanova, M, Marcellin, P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 61 (2015), 1798–1808.
16. 16 Gerber, L, Estep, M, Stepanova, M, Escheik, C, Weinstein, A, Younossi, ZM, Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 14 (2016), 156–164.
17. 17 Younossi, ZM, Stepanova, M, Nader, F, Lam, B, Hunt, S, The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 42 (2015), 286–295.
18. 18 Younossi, ZM, Stepanova, M, Henry, L, Nader, F, Hunt, S, An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 111 (2016), 808–816.
19. 19 Younossi, ZM, Stepanova, M, Henry, L, et al. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. J Viral Hepat, 2016 published online March 14. 10.1111/jvh.12528.
20. 20 Younossi, I, Weinstein, A, Stepanova, M, Hunt, S, Younossi, ZM, Mental and emotional impairment in patients with hepatitis C is related to lower work productivity. Psychosomatics 57 (2016), 82–88.
21. 21 Charlton, M, Everson, GT, Flamm, SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
22. 22 Manns, M, Samuel, D, Gane, EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16 (2016), 685–697.
23. 23 Curry, MP, O'Leary, JG, Bzowej, N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
24. 24 Ware, JE, Kosinski, M, Interpreting SF-36 summary health measures: a response. Qual Life Res 10 (2001), 405–413.
25. 25 Webster, K, Odom, L, Peterman, A, Lent, L, Cella, D, The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res, 8, 1999, 604.
26. 26 Younossi, ZM, Guyatt, G, Kiwi, M, Boparai, N, King, D, Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45 (1999), 295–300.
27. 27 Reilly, MC, Zbrozek, AS, Dukes, EM, The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4 (1993), 353–365.
28. 28 Spiegel, BM, Younossi, ZM, Hays, RD, Revicki, D, Robbins, S, Kanwal, F, Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41 (2005), 790–800.
29. 29 Walters, SJ, Brazier, JE, What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes, 1, 2003, 4.
30. 30 Younossi, ZM, Stepanova, M, Feld, J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol 65 (2016), 33–39.
31. 31 Saab, S, Ibrahim, AB, Shpaner, A, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl 11 (2005), 218–223.
32. 32 Younossi, Z, Park, H, Henry, L, Adeyemi, A, Stepanova, M, Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150 (2016), 1599–1608.
33. 33 Stepanova, M, Nader, F, Cure, S, Bourhis, F, Hunt, S, Younossi, ZM, Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther 40 (2014), 676–685.
34. 34 Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with velpatasvir and sofosbuvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from ASTRAL-2 and 3 clinical trials. Clin Infect Dis (in press).
35. 35 Younossi, ZM, Stepanova, M, Henry, L, Nader, F, Hunt, S, Interferon (IFN), ribavirin (RBV), duration of treatment and baseline patient-reported outcomes (PROs) predict adherence to the new regimens for treatment of chronic hepatitis C (CH-C). Hepatology, 62(suppl 1), 2015, 371A.
36. 36 Stepanova, M, Kanwal, F, El-Serag, HB, Younossi, ZM, Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 53 (2011), 737–745.